This invention is directed to compounds of formula (I):
wherein
m, n, R
1
, R
2
and R
3
are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.
本发明涉及以下式(I)的化合物:其中m、n、R1、R2和R3如本文中所定义,作为立体异构体、对映异构体、互变异构体或其混合物;或其药学上可接受的盐、溶剂化合物或前药,用于治疗
铁代谢紊乱。本发明还涉及包含这些化合物的药物组合物以及使用这些化合物治疗
铁代谢紊乱的方法。